



(43) International Publication Date
20 February 2014 (20.02.2014)

- (51) **International Patent Classification:**
C07D 487/16 (2006.01) *A61K 31/519* (2006.01)
C07D 498/16 (2006.01) *A61P 31/18* (2006.01)
- (21) **International Application Number:**
PCT/US2013/054532
- (22) **International Filing Date:**
12 August 2013 (12.08.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/683,772 16 August 2012 (16.08.2012) US
61/818,572 2 May 2013 (02.05.2013) US
13/959,268 5 August 2013 (05.08.2013) US
- (71) **Applicant: BRISTOL-MYERS SQUIBB COMPANY**
[US/US]; Route 206 and Province Line Road, Princeton,
New Jersey 08543-4000 (US).
- (72) **Inventors: NAIDU, B. Narasimhulu;** Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). **PATEL, Manoj;** Bristol-Myers
Squibb Company, 5 Research Parkway, Wallingford, Con-
necticut 06492 (US). **D'ANDREA, Stanley;** 15 Harvest
Lane, Wallingford, Connecticut 06492 (US). **ZHENG, Zh-
izhen Barbara;** Bristol-Myers Squibb Company, 5 Re-
search Parkway, Wallingford, Connecticut 06492 (US).
CONNOLLY, Timothy P.; Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **LANGLEY, David R.;** Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **PEESE, Kevin;** Bristol-Myers Squibb Com-
pany, 5 Research Parkway, Wallingford, Connecticut
06492 (US). **WANG, Zhongyu;** Bristol-Myers Squibb
Company, 5 Research Parkway, Wallingford, Connecticut


06492 (US). **WALKER, Michael A.**; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US). **KADOW, John F.**; Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, Connecticut 06492 (US).

- (74) **Agents:** EPPERSON, James et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION



(I)

(57) Abstract: The disclosure generally relates to compounds of formula (I), including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.